Beyond m6A modification, KIAA1429 promotes tumor growth, metastasis, and gefitinib resistance in NSCLC through multiple signaling pathways including JAK2/STAT3, EMT, PI3K/AKT, PD-L1, autophagy, ferroptosis, p53 signaling pathways (Table 6). Here, JAK2 is linked to neoplasm.